What we study

We are developing immune-integrated organoids and MPS platforms to predict the immunotoxicity of monoclonal antibodies and cancer immunotherapies.

Our platforms reconstruct immune responses in major toxicity-relevant organs, including the Liver, Kidney, Lung, Intestine, Lymph node.

We further develop interconnected multi-organ systems to investigate how local immune activation induced by immunotherapeutics can propagate into systemic immune toxicity and multi-organ injury.

By integrating experimental MPS data with computational and in silico modeling, we aim to establish reproducible and predictive platforms that can ultimately contribute to human-relevant preclinical and regulatory safety assessment.

​

Supported Project

​

• Development of Predictive Assessment Technologies for Immunotoxicity of Antibody Therapeutics
  Ministry of Food and Drug Safety, 2026–2027

​

• Development of Microsystems for Safety Assessment of Immunotherapeutics
  Korean ARPA-H Program, 2024–2029